Search Results 61-70 of 27974 for Two-phase

1. A Study of FT 2102 in Participants with Advanced Solid Tumors and Gliomas with an IDH1 Mutation - Mayo Clinic

   The study is divided into two parts: single agent FT-2102 followed by combination therapy. ... Phase 2 investigation of clinical activity in up to 4 cohorts.

2. Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 - Mayo Clinic

   The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with ...

3. Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL - Mayo Clinic

   TP-0903 is shown to block cancer cell epithelial-to-mesenchymal transitions. AXL was identified as a potential therapeutic target in chronic lymphocytic ...

4. Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 in Subjects With Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) - Mayo Clinic

   Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 in Subjects With Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION). Print ...

5. Multi-phase Dual Energy for Quantitative and Radiologic Evaluation of Chronic Liver Disease - Mayo Clinic

   The purpose of this study is to assess the combined impact of post-processing methods that quantify potential biomarkers of chronic liver disease (AEF, fECS) ...

6. TIGER-2: A Phase 2, Open-label, Multicenter, Safety and Efficacy Study of Oral CO-1686 as 2nd Line EGFR-directed TKI in Patients With Mutant EGFR Non-small Cell Lung Cancer (NSCLC) - Mayo Clinic

   TIGER-2: A Phase 2, Open-label, Multicenter, Safety and Efficacy Study of Oral CO-1686 as 2nd Line EGFR-directed TKI in Patients With Mutant EGFR Non-small Cell ...

7. A First-in-human Study of 3HP-2827 in Patients With Unresectable or Metastatic Solid Tumors With FGFR2 Alterations - Mayo Clinic

   Patients will be enrolled in two stages: dose escalation stage (Stage I) and expansion stage (Stage II). Participation eligibility. Participant eligibility ...

8. A Phase 2 Study to Evaluate Pharmacodynamics of YKP10811 in Patients With Chronic or Functional Constipation - Mayo Clinic

   A Phase 2 Study to Evaluate Pharmacodynamics of YKP10811 in Patients With Chronic or Functional Constipation · Overview · Participation eligibility · Participating ...

9. A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis - Mayo Clinic

   About this study. The purpose of trhis study is to evaluate CPI-0610 in patients who have both received JAK inhibitors, such as ruxolitinib (Arms 1 and 2), ...

10. A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer - Mayo Clinic

    A Phase 2, 2 part trial to evaluate the safety and efficacy of galeterone in castration resistant prostate cancer (CRPC) patients. Participation eligibility.